Clinical Trial Update: COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for COM701, a PVRIG inhibitor, in adults with advanced solid tumors; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Endometrial Cancer
• Lung Cancer
• Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• COM701

Snippet

Sponsor: Compugen Ltd | Conditions: Advanced Cancer, Ovarian Cancer | Phase 1 | Status: COMPLETED